Alkoxy compounds for disease treatment
First Claim
1. A method of modulating chromophore flux in a retinoid cycle comprising introducing into a subject a non-retinoid aromatic compound that inhibits 11-cis-retinol production with an IC50 of about 0.1 micromolar or less when assayed in vitro, the assay consisting of a homogenate of HEK293 cell clone expressing recombinant human RPE65 and LRAT as the source of visual enzyme, exogenous all-trans-retinol in the amount of about 20 μ
- M, recombinant human CRALBP in the amount of about 80 μ
g/mL, about 10 mM pH 7.2 phosphate buffer, about 0.5% BSA and about 1 mM NaPPi, and wherein the amount of assay reaction product 11-cis-retinol being determined by HPLC analysis following heptane extraction of the assay reaction mixture and wherein the non-retinoid aromatic compound consists of a benzene core that is substituted with a first substituent, a second substituent, and an optional third substituent, wherein the first and second substituents are attached to the benzene core in a meta-substitution configuration, wherein the first substituent is an optionally substituted 3-aminoprop-1-yl group, the second substituent is a (c-C6H11)CH2—
O—
group, and the optional third substituent is a halogen or —
OH;
wherein the optionally substituted 3-aminoprop-1-yl group has the formula —
C(R9)(R10)C(R1)(R2)CH2NH2,wherein R1 and R2 are each independently selected from hydrogen, halogen, C1-C5 unsubstituted alkyl, or —
OR6;
R9 and R19 are each independently selected from hydrogen, halogen, C1-C5 alkyl optionally substituted with hydroxy or halogen, or —
OR19, andR6, and R19 are each independently hydrogen or CH3.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt'"'"'s Disease.
37 Citations
15 Claims
-
1. A method of modulating chromophore flux in a retinoid cycle comprising introducing into a subject a non-retinoid aromatic compound that inhibits 11-cis-retinol production with an IC50 of about 0.1 micromolar or less when assayed in vitro, the assay consisting of a homogenate of HEK293 cell clone expressing recombinant human RPE65 and LRAT as the source of visual enzyme, exogenous all-trans-retinol in the amount of about 20 μ
- M, recombinant human CRALBP in the amount of about 80 μ
g/mL, about 10 mM pH 7.2 phosphate buffer, about 0.5% BSA and about 1 mM NaPPi, and wherein the amount of assay reaction product 11-cis-retinol being determined by HPLC analysis following heptane extraction of the assay reaction mixture and wherein the non-retinoid aromatic compound consists of a benzene core that is substituted with a first substituent, a second substituent, and an optional third substituent, wherein the first and second substituents are attached to the benzene core in a meta-substitution configuration, wherein the first substituent is an optionally substituted 3-aminoprop-1-yl group, the second substituent is a (c-C6H11)CH2—
O—
group, and the optional third substituent is a halogen or —
OH;
wherein the optionally substituted 3-aminoprop-1-yl group has the formula —
C(R9)(R10)C(R1)(R2)CH2NH2,wherein R1 and R2 are each independently selected from hydrogen, halogen, C1-C5 unsubstituted alkyl, or —
OR6;R9 and R19 are each independently selected from hydrogen, halogen, C1-C5 alkyl optionally substituted with hydroxy or halogen, or —
OR19, andR6, and R19 are each independently hydrogen or CH3. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
- M, recombinant human CRALBP in the amount of about 80 μ
Specification